Collectively, these show that co-existing KRAS and TP53 mutations alter transcriptional networks in pancreatic cancer, calling for reconsideration of PDAC drug regimen combinations accounting for both to restrain drug resistance. Here, TP53 is linked to pancreatic neoplasm.